Skip to content

Comparing hydromorphone vs morphine in opioid tolerance for cancer pain using patient-controlled analgesia

Comparison of patient-controlled analgesia in cancer pain: differences in tolerance between hydromorphone and morphine

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300077738
Enrollment
Unknown
Registered
2023-11-17
Start date
2023-11-30
Completion date
Unknown
Last updated
2023-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer pain

Interventions

experimental group:PCA using hydromorphone
control group:PCA using morphine

Sponsors

The First Affiliated Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age range from 18 to 80 years old, regardless of gender; 2. The patient is diagnosed as a malignant solid tumor through pathology or cytology; 3. Persistent and severe cancer related pain, VAS = 6; 4. ECOG performance status = 3; 5. Need to use opioid drugs and have not previously used opioid analgesics (Opioid naïve patients); 6. No cognitive impairment or psychiatric illness, and no radiotherapy, chemotherapy, or hormone, targeted, or bisphosphonate therapy within 7 days before randomization;7. Expected lifespan greater than 3 months; 8. Voluntarily participate in this study and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. There are objections to the treatment method of this experiment; 2. Patients with abnormal coagulation function; 3. There are contraindications for the use of opioid drugs: paralytic intestinal obstruction, brain metastasis, severe liver and kidney failure, uncontrolled nausea or vomiting; 4. Previously used any opioid drugs; 5. Patients with severe mental or other illnesses who are unable to perform pain scores correctly or objectively describe symptoms; 6. Patients who cannot be followed up on schedule; 7. Individuals who are allergic to relevant drugs and excipients; 8. Pregnancy, renal failure, uremia, diabetes, multiple sclerosis and anemia.

Design outcomes

Primary

MeasureTime frame
Opioid tolerance rate;

Secondary

MeasureTime frame
The percentage change in dose from baseline (dose change rate);Visual Analogue Scale / Score,VAS;The daily average breakthrough pain count;clinical success rate;36-item version of the Short Form Health Survey;Opioid Consumption;

Countries

China

Contacts

Public ContactTao Song

The First Affiliated Hospital of China Medical University

songt2001@163.com+86 158 4059 9900

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026